phase I clinical study
Day One Biopharmaceuticals Begins Combination Portion of Trial in MAPK-Altered Tumors
Following on a monotherapy study initiated last year, the new study will combine two of Day One's investigational compounds: a Raf kinase inhibitor and a MEK inhibitor.
Bayer Cancels Cell Therapy Licensing Deal With Atara Biotherapeutics
Bayer has notified Atara of plans to terminate its exclusive worldwide licensing deal for the mesothelin-directed cell therapies ATA3271 and ATA2271.
Aileron Begins Treating p53-Mutated Breast Cancer Patients in Study of Chemo-Protective Drug
The trial will explore whether ALRN-6924 prevents toxicity in patients receiving neoadjuvant chemotherapy treatment.
City of Hope, Imugene Begin Trial of Oncolytic Virus in Advanced Solid Cancers
The partners will see if the oncolytic virus CF33-hNIS, dubbed Vaxinia, can increase PD-L1 tumor expression and make patients responsive to Merck's Keytruda.
Odimma Therapeutics, ABL Europe Partner on Personalized Cancer Vaccine Development
ABL will manufacture the viral vector component to deliver personalized cancer neoantigens as part of Odimma's ODI-2001 platform.